These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 3798071

  • 21. [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate].
    González D, Pastrana M, Mautalen C.
    Medicina (B Aires); 1997; 57 Suppl 1():25-31. PubMed ID: 9567351
    [Abstract] [Full Text] [Related]

  • 22. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
    Papapoulos SE, Frolich M, Mudde AH, Harinck HI, vd Berg H, Bijvoet OL.
    J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE, Frölich M.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
    Vega E, Mautalen C, Roldán EJ, Pérez Lloret A.
    Drugs Exp Clin Res; 1994 Nov; 20(3):103-8. PubMed ID: 7956716
    [Abstract] [Full Text] [Related]

  • 27. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
    Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE.
    Bone; 2003 Nov; 33(5):831-8. PubMed ID: 14623059
    [Abstract] [Full Text] [Related]

  • 28. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P, Thiébaud D, Perey L, von Fliedner V.
    Recent Results Cancer Res; 1989 Nov; 116():54-66. PubMed ID: 2762665
    [Abstract] [Full Text] [Related]

  • 29. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
    Papapoulos SE, Hoekman K, Löwik CW, Vermeij P, Bijvoet OL.
    J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
    Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ.
    Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
    [Abstract] [Full Text] [Related]

  • 37. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA.
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Influence of disodium etidronate on Paget's disease of bone.
    Muir HG, Schabort I, Hough FS.
    S Afr Med J; 1987 Oct 03; 72(7):470-2. PubMed ID: 3116683
    [Abstract] [Full Text] [Related]

  • 40. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
    Delmas PD, Chapuy MC, Vignon E, Charhon S, Briancon D, Alexandre C, Edouard C, Meunier PJ.
    J Clin Endocrinol Metab; 1982 Apr 03; 54(4):837-44. PubMed ID: 6460781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.